News

A clinical study into high-frequency chest wall oscillation vests — assessing their short-term impact on standard measures of lung function before and during use — challenges the view that these devices work through airflow bias in the lungs, the process responsible for mucus movement when breathing. Findings, using established tests that include forced vital capacity…

Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor), a licensed medicine used to treat cystic fibrosis (CF) patients ages 6 and older, has now been approved by the U.S. Food and Drug Administration as the first medicine to treat CF in children ages 2-5. The approval is for children who have…

Topline data from a Phase 2b trial showed that the investigative therapy acebilustat taken once daily can reduce the number and frequency of pulmonary exacerbations in patients with cystic fibrosis (CF). It did not, however, seem to affect patients’ overall lung function. Pulmonary exacerbations — temporary worsening of lung function — are…

Cystic fibrosis is (CF) patients receiving higher doses of pancreatic enzyme replacement therapy (PERT) gain more weight, a recent report shows. PERT is a tablet that contains pancreatic enzymes. When taken with food, this therapy can improve the absorption of necessary nutrients. Many CF patients struggle with weight gain. This is…